Preparation of dendritic cell tumor-vaccine with dendritic cells and problems in its clinical uses--review.
- Author:
Zhi-Yong YU
1
;
Hu CHEN
;
Kai FENG
Author Information
1. Hematopoietic Stem Cell Transplatation Center, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100039, China.
- Publication Type:Journal Article
- MeSH:
Cancer Vaccines;
immunology;
Cell Culture Techniques;
Dendritic Cells;
immunology;
Humans;
Neoplasms;
therapy
- From:
Journal of Experimental Hematology
2004;12(3):397-400
- CountryChina
- Language:Chinese
-
Abstract:
Dendritic cell (DC), the most powerful antigen presenting cell, has been paid close attention to tumor immunotherapy. The tumor antigens were extracted by different ways to pulse DC, and then the mature DC were infused to patients to accelerate anti-tumor immuno responses. Its clinical use would provide a new therapeutic pathway other than surgical operation, irradiation, chemotherapy. In this paper, biological characteristics of DC, tumor-vaccine preparation and its clinical use were reviewed.
